At the 2026 ASCO Annual Meeting in Chicago, Sichuan Kelun-Biotech announced promising results from a Phase II study of lunbotinib fumarate, a next-generation selective RET inhibitor, for advanced RET fusion-positive non-small cell lung cancer (NSCLC). The study demonstrated an impressive objective response rate (ORR) of 81.3% in treatment-naïve patients and 87.1% in pre-treated patients, with durable responses and manageable safety profiles. A New Drug Application for lunbotinib has been accepted by China’s NMPA, indicating a potential new treatment option for patients. The drug also showed significant efficacy in patients with central nervous system metastases.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.biospace.com/press-releases/kelun-biotech-presents-pivotal-phase-ii-data-for-lunbotinib-fumarate-a400-ep0031-in-ret-fusion-positive-nsclc-at-2026-asco
